272 related articles for article (PubMed ID: 15837819)
1. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R; Surowy CS; Bianchi BR; Neelands TR; McDonald HA; Niforatos W; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
[TBL] [Abstract][Full Text] [Related]
2. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia.
McDonald HA; Neelands TR; Kort M; Han P; Vos MH; Faltynek CR; Moreland RB; Puttfarcken PS
Eur J Pharmacol; 2008 Oct; 596(1-3):62-9. PubMed ID: 18755179
[TBL] [Abstract][Full Text] [Related]
3. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
4. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
5. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
6. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
[TBL] [Abstract][Full Text] [Related]
7. Binding of [(3)H]A-778317 to native transient receptor potential vanilloid-1 (TRPV1) channels in rat dorsal root ganglia and spinal cord.
Bianchi BR; El Kouhen R; Chen J; Puttfarcken PS
Eur J Pharmacol; 2010 May; 633(1-3):15-23. PubMed ID: 20153316
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning, functional characterization of the porcine transient receptor potential V1 (pTRPV1) and pharmacological comparison with endogenous pTRPV1.
Ohta T; Komatsu R; Imagawa T; Otsuguro K; Ito S
Biochem Pharmacol; 2005 Dec; 71(1-2):173-87. PubMed ID: 16288992
[TBL] [Abstract][Full Text] [Related]
9. Cloning and pharmacological characterization of mouse TRPV1.
Correll CC; Phelps PT; Anthes JC; Umland S; Greenfeder S
Neurosci Lett; 2004 Nov; 370(1):55-60. PubMed ID: 15489017
[TBL] [Abstract][Full Text] [Related]
10. Direct activation of transient receptor potential vanilloid 1(TRPV1) by diacylglycerol (DAG).
Woo DH; Jung SJ; Zhu MH; Park CK; Kim YH; Oh SB; Lee CJ
Mol Pain; 2008 Oct; 4():42. PubMed ID: 18826653
[TBL] [Abstract][Full Text] [Related]
11. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.
Klionsky L; Tamir R; Holzinger B; Bi X; Talvenheimo J; Kim H; Martin F; Louis JC; Treanor JJ; Gavva NR
J Pharmacol Exp Ther; 2006 Oct; 319(1):192-8. PubMed ID: 16844842
[TBL] [Abstract][Full Text] [Related]
12. TRPV1b overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells.
Vos MH; Neelands TR; McDonald HA; Choi W; Kroeger PE; Puttfarcken PS; Faltynek CR; Moreland RB; Han P
J Neurochem; 2006 Nov; 99(4):1088-102. PubMed ID: 17018028
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats.
Jhaveri MD; Elmes SJ; Kendall DA; Chapman V
Eur J Neurosci; 2005 Jul; 22(2):361-70. PubMed ID: 16045489
[TBL] [Abstract][Full Text] [Related]
14. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
15. 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro.
Shimizu I; Iida T; Horiuchi N; Caterina MJ
J Pharmacol Exp Ther; 2005 Sep; 314(3):1378-85. PubMed ID: 15947039
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
17. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
18. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
Gavva NR; Tamir R; Klionsky L; Norman MH; Louis JC; Wild KD; Treanor JJ
Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
[TBL] [Abstract][Full Text] [Related]
19. Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors.
McHugh D; McMaster RS; Pertwee RG; Roy S; Mahadevan A; Razdan RK; Ross RA
J Pharmacol Exp Ther; 2006 Feb; 316(2):955-65. PubMed ID: 16207832
[TBL] [Abstract][Full Text] [Related]
20. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists.
Appendino G; Harrison S; De Petrocellis L; Daddario N; Bianchi F; Schiano Moriello A; Trevisani M; Benvenuti F; Geppetti P; Di Marzo V
Br J Pharmacol; 2003 Aug; 139(8):1417-24. PubMed ID: 12922928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
